Palvella Therapeutics (NASDAQ:PVLA) Posts Quarterly Earnings Results, Misses Expectations By $0.30 EPS

Palvella Therapeutics (NASDAQ:PVLA) announced its earnings results on Thursday. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30), FiscalAI reports.

Here are the key takeaways from Palvella Therapeutics’ conference call:

• Phase III SELVA for QTORIN rapamycin met the primary and all key secondary endpoints with a tolerable safety profile, and Palvella says an NDA submission remains on track for H2 2026 with an in-person pre-NDA meeting this quarter toward a potential H1 2027 approval.
• The company completed an upsized $230 million financing and ended Q1 with $261.9 million in cash, which management says provides runway into a potential commercial launch and through cash-flow break-even under current assumptions.
• Palvella is scaling commercial readiness—hiring experienced rare-disease launch leaders, expanding MSL coverage, and targeting a 30–40 rep field force pre-PDUFA—while estimating peak U.S. MLM sales >$1 billion and potential orphan pricing of $100k–$200k per patient per year.
• Pipeline momentum extends beyond MLM: phase III planning for cutaneous venous malformations is on track for H2 2026, the phase II LOTU angiokeratoma study has dosed its first patients ahead of schedule, and a DSAP phase II is targeted for H2 2026 amid strong patient interest.
• Management highlights the QTORIN platform as a differentiator—demonstrating dermal delivery of high‑molecular‑weight rapamycin, supported by multiple issued patents and formulation/manufacturing know‑how aimed at creating durable exclusivity and barriers to competition.

Palvella Therapeutics Stock Up 7.1%

Palvella Therapeutics stock traded up $8.03 during midday trading on Friday, hitting $121.29. 231,535 shares of the company’s stock were exchanged, compared to its average volume of 212,329. Palvella Therapeutics has a 12 month low of $20.20 and a 12 month high of $151.18. The firm has a 50-day moving average of $126.26 and a two-hundred day moving average of $102.43.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. HC Wainwright increased their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Chardan Capital upped their price target on shares of Palvella Therapeutics from $210.00 to $240.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Truist Financial set a $210.00 price target on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Finally, TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $198.07.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director George M. Jenkins purchased 4,000 shares of the stock in a transaction dated Friday, February 27th. The stock was purchased at an average price of $125.00 per share, for a total transaction of $500,000.00. Following the completion of the acquisition, the director directly owned 187,171 shares in the company, valued at approximately $23,396,375. This represents a 2.18% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 20.50% of the stock is owned by company insiders.

Institutional Trading of Palvella Therapeutics

A number of institutional investors have recently modified their holdings of the company. Invesco Ltd. boosted its holdings in shares of Palvella Therapeutics by 11.6% in the 4th quarter. Invesco Ltd. now owns 54,273 shares of the company’s stock valued at $5,681,000 after buying an additional 5,663 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Palvella Therapeutics in the 4th quarter valued at about $429,000. Virtus Investment Advisers LLC bought a new stake in shares of Palvella Therapeutics in the 4th quarter valued at about $282,000. Superstring Capital Management LP bought a new stake in shares of Palvella Therapeutics in the 4th quarter valued at about $2,666,000. Finally, Suvretta Capital Management LLC boosted its holdings in shares of Palvella Therapeutics by 8.5% in the 4th quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock valued at $93,408,000 after buying an additional 70,000 shares in the last quarter. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.